close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 -1.03 (-2.13%)
Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
News headline image
Why Novo Nordisk Stock Popped Today ↗
Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now? 
Via The Motley Fool
Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial ↗
Via Stocktwits
News headline image
2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now ↗
These dividend payers cranked up their payouts over the past decade, and they could do it again. 
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Popped Today ↗
The Wegovy maker reported positive results from a clinical trial of a next-generation obesity treatment. 
Via The Motley Fool
News headline image
Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition
Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ ↗
Via Stocktwits
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study ↗
Via Stocktwits
News headline image
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy ↗
FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days. 
Via Benzinga
News headline image
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over? ↗
Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow. 
Via Benzinga
News headline image
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment ↗
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients. 
Via Benzinga
News headline image
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap ↗
In an otherwise hot stock market, healthcare stocks are underperforming. 
Via The Motley Fool
News headline image
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders ↗
The weight loss drug market may reach $95 billion within five years. 
Via The Motley Fool
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report ↗
Via Stocktwits
Why Is Novo Nordisk’s Stock Rising Premarket Today? ↗
Via Stocktwits
Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’ ↗
Via Stocktwits
News headline image
What's Going On With Novo Nordisk Shares Monday? ↗
Novo Nordisk shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke. 
Via Benzinga
News headline image
Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact ↗
EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients. 
Via Benzinga
News headline image
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance.... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Why Novo Nordisk Stock Popped Today ↗
A price cut could help get Novo Nordisk stock back in the race against Eli Lilly. 
Via The Motley Fool
News headline image
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks ↗
FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA... 
Via Benzinga
News headline image
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
How Do Investors Really Feel About Novo Nordisk? ↗
 
Via Benzinga
News headline image
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback ↗
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
News headline image
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades ↗
A decade from now, you could regret ignoring these no-brainer stock picks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
Novo Nordisk Tightens Its Belt, Cutting 9,000 Jobs And Its Profit Outlook ↗
Novo Nordisk announced a "sweeping transformation" Wednesday as the drugmaker contends with challenges in obesity. 
Via Investor's Business Daily
News headline image
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets ↗
ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices. 
Via Benzinga
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Value Candidate with Strong Fundamentals ↗
Discover Novo Nordisk (NVO), a strong value investing candidate. It offers solid valuation, top-tier profitability, and robust growth in the pharmaceutical sector. 
Via Chartmill
News headline image
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' ↗
Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today